Jpmorgan Chase & CO Immuneering Corp Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMRX
# of Institutions
54Shares Held
9.63MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.88MShares$3.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.07MShares$1.99 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny953KShares$1.77 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD859KShares$1.6 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY742KShares$1.38 Million0.0% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $49.1M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...